Have any questions? 706-721-6582 or cts@augusta.edu
- A Phase 3 Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease
Clinical Trial
A Phase 3 Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease
The primary objective of this study is to evaluate the effectiveness of the study drug, GBT440 in adolescents and adults with Sickle Cell Disease (SCD) by observing the improvement of anemia. The secondary objectives are to evaluate the effects of GBT440 compared to placebo on SCD related symptoms and different clinical measures.
Eligibility Criteria
- SIckle Cell Disease (SS or SBO-thalassemia) Age 18-65 years
RESEARCH. INNOVATION. DISCOVERY.